Table 1.
Clinical characteristics and biochemical data between the COM and MF group.
| COM group | MF group | |||||
|---|---|---|---|---|---|---|
| Before | After | Δ (before—after) | Before | After | Δ (before—after) | |
| Age (years) | 29.96 ± 5.39 | — | — | 28.45 ± 4.74 | — | — |
| BMI (kg/m2) | 32.30 ± 3.87 | 31.21 ± 3.86## | 1.09 ± 1.09 | 29.90 ± 2.66 | 29.37 ± 2.85## | 0.53 ± 0.80 |
| WHR | 0.91 ± 0.07 | 0.91 ± 0.05 | 0.0066 ± 0.056 | 0.91 ± 0.07 | 0.90 ± 0.07 | 0.0057 ± 0.036 |
| LH (IU/L) | 6.61 ± 3.52 | 10.54 ± 12.94 | −3.93 ± 14.96 | 8.66 ± 5.76 | 10.85 ± 6.65 | −2.18 ± 6.93 |
| FSH (IU/L) | 5.73 ± 2.33 | 55.60 ± 37.72 | −1.98 ± 3.80 | 5.69 ± 1.97 | 7.37 ± 1.57 | −1.67 ± 2.86 |
| E2 (pg/ml) | 7.72 ± 2.83 | 81.20 ± 51.07 | 25.60 ± 76.26 | 59.44 ± 34.96 | 53.78 ± 17.62 | 25.66 ± 34.12 |
| TT (ng/ml) | 0.72 ± 0.31 | 0.59 ± 0.21## | 0.13 ± 0.21 | 0.71 ± 0.22 | 0.55 ± 0.17# | 0.15 ± 0.20 |
| DHAS (μg/dl) | 253.39 ± 74.15 | 252.69 ± 88.43 | 0.70 ± 50.15 | 267.45 ± 115.39 | 260.30 ± 110.99 | 7.15 ± 47.09 |
| FBG (mmol/L) | 5.16 ± 0.59 | 5.02 ± 0.45 | 0.15 ± 0.42 | 5.25 ± 0.42 | 5.28 ± 0.45 | −0.26 ± 0.30 |
| OGTT-2h BG (mmol/L) | 7.90 ± 1.44 | 7.40 ± 1.87 | 0.49 ± 2.37∗(p=0.008) | 7.24 ± 1.66 | 8.48 ± 1.56## | −1.24 ± 1.46 |
| FINS (μIU/ml) | 26.29 ± 14.38 | 22.69 ± 9.37 | 3.60 ± 12.18∗(p=0.034) | 20.04 ± 7.15 | 23.53 ± 10.28 | −3.47 ± 7.71 |
| OGTT‐2h INS (μIU/ml) | 198.99 ± 85.58∗ | 156.46 ± 92.59 | 42.53 ± 105.85 | 149.43 ± 67.21 | 131.49 ± 62.20 | 17.93 ± 79.25 |
| HbA1c | 5.46 ± 0.47 | 5.34 ± 0.42# | 0.12 ± 0.24 | 5.34 ± 0.32 | 5.31 ± 0.21 | 0.03 ± 0.23 |
| HOMA-IR | 6.17 ± 3.67 | 5.01 ± 1.94 | 1.16 ± 3.29∗ (p=0.017) | 4.53 ± 1.88 | 5.38 ± 2.56 | −0.85 ± 1.84 |
| TC (mmol/L) | 4.99 ± 0.85 | 5.29 ± 1.06 | −0.30 ± 0.87 | 5.19 ± 0.90 | 5.32 ± 0.96 | −0.53 ± 0.79 |
| TG (mmol/L) | 2.09 ± 1.64 | 2.48 ± 0.87 | −0.39 ± 1.53 | 2.26 ± 1.78 | 2.89 ± 1.60 | −0.62 ± 1.91 |
| HDL-c (mmol/L) | 1.23 ± 0.32 | 1.43 ± 0.32## | −0.20 ± 0.26 | 1.17 ± 0.20 | 1.46 ± 0.32## | −0.29 ± 0.20 |
| LDL-c (mmol/L) | 3.08 ± 0.65 | 3.07 ± 0.85 | 0.007 ± 0.813 | 3.36 ± 0.69 | 3.33 ± 0.86 | 0.02 ± 0.76 |
| ApoA1 (g/L) | 1.38 ± 0.34 | 1.65 ± 0.35## | −0.28 ± 0.34 | 1.28 ± 0.12 | 1.71 ± 0.36## | −0.43 ± 0.31 |
| ApoB (g/L) | 1.00 ± 0.17 | 0.99 ± 0.18∗ | 0.006 ± 0.176 | 1.03 ± 0.20 | 1.11 ± 0.20# | −0.082 ± 0.18 |
| LP(a) (mg/dL) | 165.86 ± 203.27 | 146.68 ± 203.30∗ | 19.18 ± 56.22 | 97.00 ± 90.44 | 53.00 ± 52.87## | 44.00 ± 51.81 |
| FFA (μmol/L) | 605.59 ± 219.38 | 647.59 ± 220.25 | −42.00 ± 215.88 | 694.60 ± 187.18 | 678.25 ± 219.07 | 16.35 ± 295.87 |
| hsCRP (mg/L) | 5.01 ± 4.46 | 4.73 ± 4.27 | 0.28 ± 4.17 | 3.69 ± 2.56 | 3.90 ± 2.90 | −0.21 ± 3.63 |
| WBC (∗10^/L) | 7.00 ± 1.19 | 7.24 ± 1.85 | −0.24 ± 1.37∗ (p=0.019) | 7, 46 ± 1.17 | 6.81 ± 1.03# | 0.65 ± 1.01 |
| ALT (U/L) | 37.92 ± 31.01 | 29.32 ± 20.26 | 8.60 ± 19.35 | 32.57 ± 17.28 | 37.05 ± 46.09 | −4.48 ± 38.16 |
| Cr (μmol/L) | 60.96 ± 9.51 | 59.13 ± 8.17 | 1.83 ± 5.68 | 60.33 ± 6.06 | 56.71 ± 7.63# | 3.62 ± 5.2 |
BMI, body mass index; WHR, waist-hip ratio; FBG, fasting blood glucose; TT, total testosterone; DHAS, dehydroepiandrosterone sulfate; OGTT, oral glucose tolerance test; HbA1c, hemoglobin A1C; Fins, fasting serum insulin; OGTT-2h INS, 2-hour insulin in OGTT. HOMA-IR, homeostasis model assessment-insulin resistant; TC, total Cholesterol; TG, triglycerides; HDL-c: high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; ApoA1, lipoprotein A1; ApoB, lipoprotein B; LP(a), lipoprotein-a; FFA, free fatty acid; hsCRP, high-sensitivity C-reactive protein; DC, white blood cell count; ALT, alanine aminotransferase; Cr, creatinine. Homeostasis model assessment-Insulin resistant (HOMA-IR) = fasting serum insulin (mIU/L) × fasting blood glucose (FBG, mmol/L)/22.5 [11]. ∗Significant difference between the COM group and MF group (∗P < 0.05, ∗∗P < 0.01). #Significant increase or decrease after treatment in the COM group or MF group (#P < 0.05, ##P < 0.01).